Chipscreen(SH:688321) Zheng Quan Zhi Xing·2025-07-17 09:17Group 1 - The company forecasts a significant increase in revenue and net profit for the first half of 2025, with an expected revenue increase of 10,512.95 thousand yuan, representing a 35% year-on-year growth [1] - The net profit attributable to the parent company is projected to be approximately 2,119.00 thousand yuan, reflecting an increase of 6,836.82 thousand yuan or 145% compared to the same period last year [1] - The company reported a revenue of 30,216.05 thousand yuan and a net loss of 4,100.64 thousand yuan for the first half of 2024 [1] Group 2 - The primary reasons for the expected performance improvement include the new inclusion of the product Sidabamine for diffuse large B-cell lymphoma in medical insurance and optimized sales strategies for Siglecin, which have led to significant sales growth [1] - The company anticipates a 43% year-on-year revenue growth and a 51% quarter-on-quarter growth for the second quarter of 2025, with a turnaround to profitability for the net profit attributable to the parent company [1]